CD markers Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S8960 CD38 inhibitor 1 (compound 78c) CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively.
Leukemia, 2025, 10.1038/s41375-025-02551-4
J Nanobiotechnology, 2025, 23(1):457
Cell Rep Med, 2024, 5(2):101400
S5525 SodiuM Metatungstate Sodium metatungstate (SMT) solution is an inorganic heavy liquid which is widely used in density fractionation. Sodium metatungstate (Sodium polyoxotungstates) is a potent and selective inhibitor of ecto-nucleoside triphosphate diphosphohydrolase (NTPDases, CD39) with Ki of 0.140 μM, 0.910 μM and 0.563 μM for NTPDase1, NTPDase2 and NTPDase3, respectively.
Cancer Immunol Immunother, 2024, 73(6):108
Immunology, 2022, 10.1111/imm.13493
Cancer Cell, 2021, 39(7):973-988.e9
S9867 LY-3475070 LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase).
Theranostics, 2024, 14(3):1224-1240
Immunology, 2022, 10.1111/imm.13493
S3301 Cynarin Cynarin (Cynarine) is an artichoke phytochemical that possesses a variety of pharmacological features including free-radical scavenging, antioxidant, antihistamic and antiviral activities. This compound blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. It triggers Nrf2 nuclear translocation, restores the balance of glutathione (GSH) and reactive oxygen species (ROS), and inhibits mitochondrial depolarization.
Int J Mol Med, 2025, 56(6)206
S0141 NQ301 NQ301 (Compound 211), an antiplatelet and antithrombotic agent, is a selective CD45 inhibitor with IC50 of 200 nM. This compound inhibits thromboxane A2 receptor (TXA2) and synthase activity in rabbit platelets.
J Extracell Vesicles, 2021, 10(5):e12078
S6727 AX-024 HCl AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). This compound also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
Cell Rep Med, 2025, S2666-3791(25)00231-9
E4693New AC-73 AC-73 is a first specific, orally active and potent inhibitor of CD147. It exerts anti-proliferative effects by inducing autophagy and enhancing chemotherapeutic sensitivity in acute myeloid leukemia (AML) cells, while also inhibiting Hepatocellular carcinoma (HCC) mobility and invasion through suppression of the CD147/ERK1/2/STAT3/MMP-2 pathway, making it valuable for AML and HCC research.
S8908 AB680 AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73.
E1276 MK-0159 MK-0159 (Compound 37) is an inhibitor of CD38. This compound inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. It increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
E1305 RBN013209 RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer.
E5853New SMS121 SMS121 is a potent inhibitor of CD36 with a Kd value of 5.57 µM. It impairs fatty acid uptake, as well as the viability and proliferation of acute myeloid leukemia (AML) cells, indicating its potential as a future therapeutic agent against AML.
S2632 BMS-378806 BMS-378806 (BMS 806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.
Commun Biol, 2025, 8(1):442
Commun Biol, 2023, 6(1):535
J Virol, 2021, 95(24):e0052921
S7487 YYA-021 YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4.
S6347 5'-N-Ethylcarboxamidoadenosine (NECA) 5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. It acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.